These studies have pointed the way forward to future clinical trials of radiotherapy/cisplatin plus Plerixafor or other newly emerging CXCL12 or CXCR4 inhibitors in women with cervical cancer.
The objective of this study was to explore the efficacy and toxicity of combining RTCT with CXCL12/CXCR4 inhibition in cervical cancer.<b>Experimental Design:</b> CXCR4 expression was measured in 115 patients with cervical cancer.
The aim of this study was to assess the association of TNF-α/rs1799724 and CXCL12/rs266085 polymorphisms with susceptibility to cervical cancer in Han Chinese population in Shandong Province.
These findings suggested that the SDF1‑3' G801A polymorphism may be a genetic risk factor for cervical cancer in patients with a positive history of tobacco smoking.